GLP-1 lawsuits explained: 3,200 federal cases against Novo and Lilly

Last reviewed: April 16, 2026

The GLP-1 litigation wave is the biggest pharmaceutical mass tort since the opioid cases. Novo Nordisk and Eli Lilly are the named defendants in over 4,400 combined lawsuits, and plaintiff attorneys estimate total liability between $10 billion and $50 billion depending on how bellwether trials land.

If you took semaglutide, tirzepatide, liraglutide, or any compounded version and ended up hospitalized, you probably have questions. This guide explains the MDL, the allegations, the timeline, and what the parallel lawsuits against telehealth compounders mean for patients.

What are the main allegations against Novo and Lilly?

Plaintiffs allege the manufacturers failed to warn about the severity, duration, and frequency of gastrointestinal injuries, along with ocular and neurological risks that don't appear prominently on current labels. The core legal theory is inadequate labeling, not that the drugs were defective in manufacture.

The injury list reads like a hospital admission log. Gastroparesis, which is stomach paralysis that can last years after stopping the drug, shows up in the largest share of claims. Ileus, a complete bowel obstruction, has triggered emergency surgery in hundreds of plaintiffs. Pancreatitis and gallbladder disease are older known risks, but attorneys argue the frequency in real-world use exceeds what trial data suggested.

The newer wave of claims covers NAION, a sudden blood flow failure to the optic nerve that causes permanent vision loss or blindness. A 2024 Harvard study linked semaglutide to a 4x higher NAION risk, and that paper is cited in nearly every ocular injury complaint. Neurological injuries and tinnitus are the latest additions, with GLP-1 tinnitus lawsuits emerging through late 2025.

What is the MDL and how does it work?

An MDL, or Multidistrict Litigation, consolidates similar federal lawsuits in front of one judge for pretrial proceedings. The GLP-1 MDL sits in the Eastern District of Pennsylvania under Judge Gene Pratter's successor bench. Consolidation doesn't merge the cases into a class action. Each plaintiff keeps their individual claim, but discovery, expert witness rulings, and motion practice happen once for everyone.

The Pennsylvania venue matters. Novo Nordisk's US headquarters is in Plainsboro, New Jersey, and Lilly sits in Indianapolis, so the Eastern District of Pennsylvania was chosen as neutral turf with deep pharmaceutical MDL experience. The court has already ruled on preemption motions from both defendants, which the companies lost in March 2026.

Lawsuit tracker

When will the bellwether trials start?

The first bellwether trials are scheduled for September 2026, roughly three years after the earliest cases were filed. Bellwethers are test trials. The judge and lead counsel select a small group of representative cases, usually six to twelve, that go in front of juries first. The verdicts signal to both sides what the wider population of claims is worth, which drives settlement negotiations.

The first tranche will likely focus on gastroparesis and ileus claims because those have the strongest causation evidence and the largest number of plaintiffs. NAION and tinnitus cases are expected in a second bellwether wave in 2027. If Novo or Lilly lose the opening trials with verdicts over $50 million per plaintiff, a global settlement becomes the likely exit.

Both companies have publicly said the claims lack merit and point to safety profiles already documented on their labels. Novo's Ozempic label was updated in 2023 to include ileus warnings after FDA pressure, which plaintiff attorneys cite as an admission that the earlier label was inadequate.

Lawsuits against telehealth providers (Hims, Henry Meds, NextMed)

Parallel to the MDL, a separate legal war is playing out against telehealth compounders. These cases matter because most GLP-1 users during the 2023 to 2025 shortage took compounded versions, not brand-name Ozempic or Zepbound. Compounded product quality varies wildly, and testing has exposed major problems.

Novo Nordisk sued Hims in February 2026, alleging patent infringement and that Hims-sold compounded semaglutide tested at 86% impurity. The suit was dismissed in March 2026 after the two companies signed a partnership deal giving Hims direct Wegovy access. The 86% impurity claim never went to trial, but the data is now public.

Eli Lilly sued Henry Meds, Mochi Health, Fella Health, and Willow in April 2025 over untested oral tirzepatide formulations. Oral tirzepatide isn't FDA approved, and Lilly's position is that selling it is per se unsafe. The FTC separately fined NextMed $150,000 in July 2025 for deceptive ads and finalized the order in December 2025. OpenLoop and Triad Rx face a class action alleging their compounded oral GLP-1 products caused anaphylactic shock in multiple patients.

What the 86% impurity finding means for compounded users

An 86% impurity reading means only 14% of the product was actual semaglutide. The rest was process byproducts, unreacted starting materials, or unknown compounds. For context, USP standards require compounded sterile injectables to hit 90%+ purity at minimum. A 14% active ingredient sample would fail pharmacy inspection anywhere in the United States.

If you injected compounded semaglutide between 2023 and early 2026, there's no way to know retroactively what was in your vial. Quality varied by pharmacy. Some 503A and 503B compounders hit 98%+ purity consistently. Others, per FDA warning letter data, had contamination, dosing errors, and unidentifiable compounds. You can track individual provider enforcement history in our FDA warning letters tracker.

The 86% Hims result is cited in class actions because it undermines the "same drug, lower price" pitch that telehealth companies used. It also feeds into the Vanderbilt 2025 research showing 9% midface volume loss per 10kg lost, the "Ozempic face" phenomenon. Rapid weight loss from high-dose or inconsistent compounded product correlates with more aesthetic side effects.

What should you do if you experienced a severe side effect?

First step is medical. If you're currently symptomatic, get to a gastroenterologist or your prescribing physician. Gastroparesis diagnosis requires a gastric emptying study, and NAION needs an ophthalmologist within days of vision change. Document everything. Save receipts, prescription records, shipping labels from compounders, and photos of the medication vials.

Second step is legal, if you want to pursue it. The MDL is still accepting new plaintiffs as of April 2026. Statute of limitations varies by state, but most allow two to four years from injury discovery. Law firm intake is free, and contingency fees apply only if you win or settle. Be wary of advertising-heavy firms that take 40%+ cuts. Reputable mass tort firms cap at 33% plus expenses.

Third step is prevention if you're still taking a GLP-1. Use licensed providers with transparent sourcing. Our provider directory lists every vetted US telehealth option with their compounding partners disclosed. If you want to talk to a clinician about switching to brand-name product, you can start a consultation. And if you're weighing whether the drugs are worth the risk at all, read our guide to GLP-1 side effects and the full state of GLP-1 telehealth 2026 report.

Frequently asked questions

Am I eligible to join the GLP-1 MDL?

You qualify if you took Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, or Victoza and were diagnosed with gastroparesis, ileus, pancreatitis, gallbladder disease, NAION, or documented neurological injury. Compounded product users may qualify depending on state law and which pharmacy filled your script. Most firms offer free case evaluations.

How long will the GLP-1 lawsuits take to resolve?

Bellwether trials start September 2026, but global resolution usually takes three to five years after first verdicts. Expect major settlement movement in 2027 to 2028 if plaintiffs win the early cases. Individual payouts typically arrive one to two years after settlement is announced.

How much could a GLP-1 lawsuit settlement be worth?

Plaintiff attorneys estimate total MDL liability at $10 billion to $50 billion. Per-plaintiff values range widely, from around $50,000 for mild gastroparesis claims to $2 million+ for permanent blindness or death cases. Actual numbers depend entirely on bellwether results.

Can I sue the telehealth company that prescribed my compounded GLP-1?

Potentially yes. Telehealth provider liability depends on whether they made safety claims they couldn't back up, used a pharmacy with FDA violations, or failed to warn you about compounded product risks. The Hims, Henry Meds, and OpenLoop cases are setting precedent for 2026 and 2027 filings.

Does the Hims and Novo partnership affect the lawsuit?

The February 2026 patent case was dismissed in March 2026 after Hims and Novo struck a partnership deal. But individual plaintiffs who took compounded Hims semaglutide before the deal still have product liability claims open against both Hims and the compounding pharmacies.

Are brand-name Ozempic and Wegovy safer than compounded versions?

Brand-name products have verified purity and consistent dosing. Compounded versions vary by pharmacy, with the Hims 86% impurity finding being the most public failure. That said, brand-name product carries the same gastroparesis and NAION risks that drive the MDL. Safer means more predictable, not risk-free.

Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your healthcare provider before starting any medication. Individual results vary. FormBlends is a licensed telehealth platform; nothing here replaces a personal clinical evaluation.